ConductScience.org, home

Paper8348686

Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype.

Sadoshima J and 1 other. Circ Res, 1993. Cited by 1,257 papers, by iCite.

Cite this record

ConductScience Library. Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Papers, record 8348686. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8348686

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype.
PubMed
Journal
Circ Res
PubMed
Year
1993
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
1,257
iCite
Relative citation ratio, by iCite
31.8
iCite
Revised in PubMed
2019-07-06
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sadoshima JJ
2Izumo SS

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Angiotensin IIMajor topic
CardiomegalyMajor topic
MyocardiumMajor topic
Receptors, AngiotensinMajor topic
Angiotensinogen
Animals
Cells, Cultured
Fibroblasts
Gene Expression Regulation
Genes, fos
Hyperplasia
Rats
Transforming Growth Factor beta

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03219632Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECGBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by295

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,257 citations.

PMIDTitleJournalYearIn PapersSource
42696246Protective Effect of a Polyherbal Formulation (Cardojith) Against Angiotensin II-induced Hypertension and Cardiomyocyte Hypertrophy Via Modulation of Oxidative Stress and MAPK Signalling.Appl Biochem Biotechnol2026https://conductscience.org/library/papers/42696246PubMed
42639029Investigating angiotensin II concentration in modulating Plasmodium falciparum infection and angiotensin receptor activation.Front Parasitol2026https://conductscience.org/library/papers/42639029PubMed
42076069Ex Vivo Buccal Permeability of Nanostructured Lipid Carriers (NLCs) Associated with a Peptide Drug Model.Pharmaceutics2026https://conductscience.org/library/papers/42076069PubMed
41542600Genetic deletion of cytoglobin exacerbates cardiac hypertrophy and inhibits cardiac fibroblast activation independent of changes in blood pressure.bioRxiv2026https://conductscience.org/library/papers/41542600PubMed
41209135The Association of Angiotensin Converting Enzyme and Angiotensinogen Gene Polymorphism With Dilated Cardiomyopathy: A Systematic Review and Meta-Analysis.Rev Cardiovasc Med2025https://conductscience.org/library/papers/41209135PubMed
40943161Beneficial Effects of Chymase Inhibition on Cardiac Diastolic Function and Remodeling Induced by Chronic Angiotensin II Stimulation.Int J Mol Sci2025https://conductscience.org/library/papers/40943161PubMed
40931092Heart failure-specific cardiac fibroblasts contribute to cardiac dysfunction via the MYC-CXCL1-CXCR2 axis.Nat Cardiovasc Res2025https://conductscience.org/library/papers/40931092PubMed
40894880Carfilzomib-specific proteasome β5/β2 inhibition drives cardiotoxicity via remodeling of protein homeostasis and the renin-angiotensin-system.iScience2025https://conductscience.org/library/papers/40894880PubMed
40872727The Renin-Angiotensin-Aldosterone System (RAAS): Beyond Cardiovascular Regulation.Vet Sci2025https://conductscience.org/library/papers/40872727PubMed
40548179The Alleviative Effect of Naringin Against Cardiovascular Dysfunction and Remodeling in Hypertensive Rats by Suppressing the Angiotensin II Pathway.Food Sci Nutr2025https://conductscience.org/library/papers/40548179PubMed
40332211Seven Deadly Sins in Hypertension Management: In-Depth Analysis of the Errors on a Journey from Riva-Rocci to Myocardial Fibrosis.Arq Bras Cardiol2025https://conductscience.org/library/papers/40332211PubMed
40267335Angiotensin II-induced cardiac fibrosis and dysfunction are exacerbated by deletion of cGKI in periostin+ myofibroblasts.Clin Sci (Lond)2025https://conductscience.org/library/papers/40267335PubMed
40028060Angiotensin II-Induced Hypertrophy in H9c2 Cells Reveals Severe Cytotoxicity of Graphene Oxide.ACS Omega2025https://conductscience.org/library/papers/40028060PubMed
39830783Advances in Selenium and Related Compounds Inhibiting Multi-Organ Fibrosis.Drug Des Devel Ther2025https://conductscience.org/library/papers/39830783PubMed
39712736Shakuyaku-Kanzo-To Prevents Angiotensin Ⅱ-Induced Cardiac Hypertrophy in Neonatal Rat Ventricular Myocytes.Cureus2024https://conductscience.org/library/papers/39712736PubMed
39638825A multi-omics approach identifies the key role of disorders of sphingolipid metabolism in Ang II-induced hypertensive cardiomyopathy myocardial remodeling.Sci Rep2024https://conductscience.org/library/papers/39638825PubMed
39475011Left atrial function in uraemic patients: Four-dimensional automatic left atrial quantitative technology study.ESC Heart Fail2025https://conductscience.org/library/papers/39475011PubMed
39452290FGFR4 Is Required for Concentric Growth of Cardiac Myocytes during Physiologic Cardiac Hypertrophy.J Cardiovasc Dev Dis2024https://conductscience.org/library/papers/39452290PubMed
39078503Sex-based differences in left ventricular mass reduction across angiotensin II receptor blockers in patients with heart failure with preserved or mildly reduced ejection fraction.Heart Vessels2025https://conductscience.org/library/papers/39078503PubMed
39076280Healing the Ischaemic Heart: A Critical Review of Stem Cell Therapies.Rev Cardiovasc Med2023https://conductscience.org/library/papers/39076280PubMed

See all 295 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
AGT183PubTator's text mininghttps://conductscience.org/library/genes/183

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8348686

GET https://conductscience.org/api/papers/v1/8348686/cited_by?page=2